The Conversation (0)
BlinkLab Limited Investor Kit
- Corporate info
- Insights
- Growth strategies
- Upcoming projects
GET YOUR FREE INVESTOR KIT
BlinkLab Limited
Investor Insight
BlinkLab’s transformative AI-based healthcare technology is at the forefront of innovations in the global medical field that are quickly gaining traction among keen investors.
Overview
BlinkLab (ASX:BB1) offers a smartphone-based diagnostic platform that leverages computer vision, artificial intelligence (AI) and machine learning (ML). A company started by neuroscientists at Princeton University, Blinklab has developed its novel technology over several years, providing an app-enabled, smartphone-based diagnostic tool for evaluating children with neurodevelopmental conditions such as autism and ADHD.
The app turns a smartphone into a diagnostic tool that helps to conduct remote and rapid tests that can assist in diagnosing neurodevelopmental conditions. BlinkLab’s smartphone app provides a screening tool that can help with diagnoses much earlier than the age that children are typically assessed at present (approximately 5-6 years old). It is also a remote (i.e., accessible) and inexpensive means of beginning the assessment process, which can typically be very costly and take up to multiple years currently.
BlinkLab’s smartphone app facilitates early diagnosis, reduces costs, and improves accuracy.
BlinkLab’s smartphone-based technology, which uses AI and machine learning (ML), makes it attractive to investors. Like other industries, AI is becoming very popular in the healthcare sector. According to Statista, the AI healthcare market is expected to proliferate from $11 billion in 2021 to $187 billion in 2030. The increasing use of AI is driven by advanced ML algorithms, access to data, and use of 5G technology. AI and ML technologies can evaluate and analyze enormous volumes of data faster than humans.
Artificial intelligence, and particularly machine learning, has the potential to serve as the great equaliser for many behavioural healthcare concerns like autism. According to recent data, 97 percent of adults in the United States own a cellular device, and nine in ten own a smartphone. A 2022 Global State of Digital report by We Are Social shows 66.9 percent, or about 5.34 billion, of the world’s population are mobile users. As these percentages continue to rise and internet-powered devices become ubiquitous, access to digital health services can become democratised on a global scale. While autism spectrum disorder (ASD) services are currently restricted to relatively privileged populations, digital solutions powered by emerging data, science, and methodologies can make access to autism therapy more accessible.
Large players are investing in this segment to tap into the vast potential of these new technologies. One such example was Pfizer’s acquisition of ResApp. In October 2022, Pfizer acquired Queensland University startup ResApp Health for $179 million. ResApp developed a smartphone technology to detect respiratory diseases using cough analysis accurately.
Furthermore, big tech companies such as Apple, Amazon, Microsoft and Alphabet are also now venturing into the AI healthcare market.
Company Highlights
- Australia-based BlinkLab (ASX:BB1) is focused on transforming mental healthcare through an AI-enabled smartphone application, a breakthrough technology developed with Princeton University.
- The company’s innovative approach leverages the power of smartphones, AI and machine learning to deliver screening tests specifically designed for children as young as 18 months old. This marks a significant advancement, considering traditional diagnoses typically occur around five years of age, often missing the crucial early window for effective intervention.
- Once approved by regulators, this cutting-edge digital technology is poised to capture the imagination of both investors and major pharmaceutical companies, eager to embrace transformative solutions in healthcare.
- BlinkLab is led by an experienced management team and leading experts in the field of machine learning, autism and brain development, bridging the most advanced technological innovations with groundbreaking scientific research. The company is chaired by Brian Leedman, an experienced biotechnology entrepreneur and founder of ResApp Health, a digital diagnostic company recently acquired by Pfizer.
Key Technology and Applications
Neurobehavioral assays of brain function can reveal fundamental mechanisms underlying neuropsychiatric conditions, but typically require centrally located equipment in a laboratory test facility. Consequently, these tests are often unpleasant for participants, as they often require instruments attached to their face and cannot be used at scale in daily clinical practice, particularly with paediatric patients.
BlinkLab has developed a smartphone-based software platform, known as ‘BlinkLab Test’, to perform neurobehavioural testing that is free from facial instruments or other fixed location equipment.
This AI-based platform is designed to be used at home or in similarly comfortable environments, either independently or with the assistance of a caregiver, while following instructions from the smartphone application. The tests include, but are not limited to, eyeblink conditioning (EBC), which is a form of sensory-motor associative learning, prepulse inhibition of the acoustic startle response (PPI), which measures the ability to filter out irrelevant information through sensorimotor gating, startle habituation, which measures the ability for the intrinsic damping of repetitive stimuli and sensory adaptation, and habituation of the eye blink response, which serve as biomarkers for neurological and psychiatric disorders.
The BlinkLab Test App combines a smartphone’s ability to deliver stimuli and acquire data using computer vision with a secure cloud-based portal for data storage and analysis. In the tests, each audio and/or visual stimulus is presented with millisecond-precise control over parameters such as timing, amplitude and frequency. To maintain participant attention, an entertaining movie of choice is shown with normalised audio levels. Participants’ responses are measured by the smartphone’s camera and microphone, and are processed in real time using state-of-the art computer vision techniques. Response data is then fully anonymised, and transferred securely to the analysis portal. There, BlinkLab’s in-house AI/ML algorithms then perform clustering and statistical analysis to identify the prediction value of the experiment in the particular data set.
BlinkLab Test was initially developed as a prescription diagnostic aid to healthcare professionals (HCP) considering the diagnosis of ASD in patients 18 months through 72 months of age that are at risk for developmental delay. In collaboration with Princeton University in the United States and Erasmus Medical Center in the Netherlands, the company has conducted several trials using BlinkLab Test as an early assessment tool for autism. Autism represents a global challenge, with 1 in 36 children in the U.S. having autism, up from the previous rate of 1 in 44. With no early tests currently available to detect the condition, many children are diagnosed with the condition as late as the age of five.
Blinklab’s mobile app can aid in early detection, facilitating diagnoses as early as two years of age and resulting in earlier personalised interventions and monitoring. The testing process is also far more comfortable than traditional means of diagnoses, as the child can watch their favourite movie or cartoon on the phone, and the app will record their reactions, providing key information on the functioning of the brain.
BlinkLab will be subject to regulatory oversight as a medical device and must clear clinical studies. Previous clinical trials completed by Blinklab have shown impressive indicators of success, achieving sensitivity levels of 85 percent and specificity levels of 84 percent. The company notes that these trials are very similar to those that are required by the United States Food and Drug Administration (FDA) for approval and have shown much higher levels of accuracy compared to currently approved products.
In order for the BlinkLab Test technology to be used as a clinical aid in the diagnosis of ASD, BlinkLab will need to complete a pivotal registrational study, and subsequently apply for FDA registration and reimbursement for the tests. The registrational study intends to recruit up to 500 subjects. Enrolment for this study is expected to begin in 2024, with study completion expected by mid-2025. The potential to participate in a disruptive and scalable AI-powered technology close to regulatory approval should attract attention from big medical technology companies.
Research and clinical studies
BlinkLab engages and partners with research and medical institutions across the globe to further test and develop its technology.
In May 2024, BlinkLab initiated a clinical study in partnership with US-based Turning Pointe Autism Foundation to enroll up to one hundred children previously diagnosed with autism and one hundred children without an autism diagnosis. The data obtained during this collaboration will be used to finalise the data collection and processing algorithms and AI/ML models ahead of the FDA registrational study.
The company is also participating in a clinical study of patients with spinocerebellar ataxias, conducted by Columbia University, New York, to study the effect of aerobic physical exercise on neuroplasticity in adults with spinocerebellar ataxias (SCA).
To further improve and accelerate the diagnostic evaluation of ADHD, BlinkLab forged a major research and clinical partnership with Mental Care Group (MCG) in The Netherlands, the fifth largest outpatient mental health care provider in Europe.
To validate BlinkLab’s platform for the assessment of functional neurological disorder (FND), the company has partnered with Bates College in Maine for a clinical study that aims to characterise the behavioural time course of Pavlovian eyeblink conditioning and acoustic startle habituation. It will validate the BlinkLab smartphone test for use as a remote neurobehavioral testing and diagnostic tool for FND.
At Erasmus University Medical Center, BlinkLab’s smartphone-based remote assessment, including eyeblink conditioning and prepulse inhibition of the acoustic startle reflex, is being used, among other tools, in a clinical study to set-up an overarching at-home testing lab, named the Digital Dementia Lab, to identify, develop and test a variety of digital biomarkers
measuring clinically relevant behaviour for improving early accurate diagnosis of dementia.
BlinkLab is also working with Monash University in Australia to evaluate BlinkLab as a medical device for monitoring the therapeutic effects of ketamine on cognitive processes whereby sensory information is converted into decision making. Results from this study can help facilitate cognitive behavioural therapy outcomes in patients with psychiatric conditions such as depression, schizophrenia, epilepsy, and post-traumatic stress disorder.
BlinkLab also recently signed a partnership for more clinical trialling with INTER-PSY, a large centre in the Netherlands that specialises in autism, offering assistance with diagnostics and treatments. This study also mirrors the study design of the Company’s developing FDA regulatory trial, which will be needed for future approval of BlinkLab Test as an approved diagnostic tool in the United States.
Management Team
BlinkLab is led by an experienced management team and directors with a proven track record in building companies and vast knowledge in digital healthcare, computer vision, AI and machine learning. The company’s chairman, Brian Leedman, is an experienced biotechnology entrepreneur and founder of ResApp Health, a digital diagnostic company for respiratory conditions, which was recently acquired by Pfizer for $179 million before reaching FDA approval for their main diagnostic product.
Dr. Henk-Jan Boele – Founder and Chief Executive Officer
Henk-Jan Boele is an assistant professor of neuroscience at the Medical Center of Erasmus University and a researcher at Princeton University. He obtained his PhD from Erasmus University in 2014. Boele has always been pushing scientific and methodological boundaries, and received numerous government and industry grants in the field of neuroscience.
Peter Boele – Founder and Chief Technology Officer
Peter Boele holds a bachelor’s degree in history and philosophy from Leiden University. He has over 20 years of experience in software development and has worked with Erasmus University, Leaseweb, Kaboom Informatics and Insocial.
Dr. Anton Uvarov – Founder and Chief Operational Officer
Anton Uvarov holds a Ph.D. from the University of Manitoba and an MBA from the Haskayne School of Business. He has rich experience in bio-technology investments with a particular focus on neuroscience and has successfully led several IPOs. He started his career as a biotechnology analyst with Citigroup, US.
Dr. Bas Koekkoek – Founder and Chief Scientific Officer
Bas Koekkoek is an assistant professor at Erasmus Medical Center. Koekkoek has been working at the Department of Neuroscience mainly in the role of rapid prototype of new technology and techniques for neuroscience. He has numerous publications in the area of brain development including Nature and Science journals.
Professor Sam Wang – Founder and Chair of Advisory Board
Sam Wang holds a PhD from Stanford University. He is a professor of neuroscience at Princeton University, has published over 100 articles on the brain in leading scientific journals and has received numerous awards. He gives public lectures on a regular basis and has been featured in The New York Times, The Wall Street Journal, NPR, and the Fox News Channel.
Professor Chris de Zeeuw – Founder and Scientific Advisor
Chris de Zeeuw is chairman of the Department of Neuroscience at Erasmus MC in Rotterdam and vice-director at the Netherlands Institute for Neuroscience in Amsterdam. De Zeeuw has received over 100 grants, including the Pioneer Award from ZonMw and the ERC advanced grant. In 2006, he received the Beatrix Award for Brain Research from Her Majesty the Queen; in 2014, he became an elected member of the Dutch Academy of Arts & Science; and in 2018, he received the international Casella Prize for Physiology.
Revolutionising Mental Health Care Through Mobile Solutions
RemSense Technologies: Enabling Industrial Digital Transformations
RemSense Technologies Limited (ASX:REM) is an Australian technology company driving digital transformation in asset-intensive industries through advanced asset visualisation and drone services. Founded in 2006 as a developer of drone systems for the defence and industrial sectors, RemSense expanded into professional drone services in 2012.
In 2019, the company broadened its focus to include high-resolution 3D asset capture and visualisation, leading to the creation of its flagship platform, virtualplant. This evolution reflects broader trends in digital transformation across sectors such as energy, resources, infrastructure, and utilities. RemSense was listed on the Australian Securities Exchange in 2021.
RemSense is strongly positioned to capitalise on the accelerating adoption of digital twin technologies, particularly across the mining, oil and gas, manufacturing, utilities, defence, marine, and aerospace sectors. As these industries increasingly turn to digital solutions to enhance safety, reduce costs, and optimise asset management, demand for RemSense’s innovative offerings continues to grow.
Company Highlights
- Profitable Growth: Delivered $3.12 million in revenue in H1 FY25 – a 178 percent increase year-over-year
- Tier-1 Client Base: Trusted by major global operators including Chevron, Newmont and Woodside Energy for digital twin and drone technology services.
- Flagship Platform – virtualplant: A scalable, cutting edge digital twin solution providing real-time operational insights for industrial facilities and infrastructure.
- Strong legacy drone operations: RPAS Services features CASA-certified pilots and a fleet of custom-engineered drones supporting multiple industrial applications.
- Serving Critical Industries: Solutions deployed across energy, resources, utilities and infrastructure sectors undergoing rapid digital transformation.
This RemSense Technologies profile is part of a paid investor education campaign.*
Click here to connect with RemSense Technologies (ASX:REM) to receive an Investor Presentation
RemSense Technologies
Investor Insight
With its flagship platform, virtualplant, already in commercial use across high-value industrial assets, and a growing global footprint through strategic partnerships, RemSense offers investors a unique opportunity to back a scalable, revenue-generating business at the forefront of digital transformation in the resource and infrastructure sectors.
Overview
RemSense Technologies Limited (ASX:REM) is an Australian technology company enabling digital transformation across resource-heavy industries through advanced asset visualisation and drone services. Originally established in 2006 as a developer of drone systems for the defence and industrial sectors, the company expanded into professional drone services in 2012.
In 2019, RemSense made a strategic expansion into high-resolution 3D asset capture and visualisation, culminating in the development of its flagship product, virtualplant. This strategic shift aligns with macro trends in digital transformation, particularly in asset-heavy industries like energy, resources, infrastructure and utilities. The company was listed on the Australian Securities Exchange in 2021.
RemSense is ideally positioned to leverage the growing adoption of digital twin technologies, particularly across mining, oil & gas, manufacturing, utilities, defence, marine and aerospace industries. These sectors are increasingly embracing digital tools to improve safety, reduce costs, and manage assets more efficiently, creating strong and expanding demand for RemSense’s solutions.
In the first half of FY25, RemSense reported $3.12 million in revenue, representing a 178 percent increase over the same period in FY24. The company also recorded its first-ever net profit of $796,892 and achieved positive operational cashflow of $365,539 – a turning point that demonstrates both commercial traction and disciplined financial execution.
Strategic partnerships with Chevron, Newmont Mining and Woodside Energy highlight RemSense’s growing reputation among Tier-1 clients and its ability to scale internationally. These engagements are not pilot programs, but are real, revenue-generating contracts that reinforce RemSense’s value proposition.
Company Highlights
- Profitable Growth: Delivered $3.12 million in revenue in H1 FY25 – a 178 percent increase year-over-year
- Tier-1 Client Base: Trusted by major global operators including Chevron, Newmont and Woodside Energy for digital twin and drone technology services.
- Flagship Platform – virtualplant: A scalable, cutting edge digital twin solution providing real-time operational insights for industrial facilities and infrastructure.
- Strong legacy drone operations: RPAS Services features CASA-certified pilots and a fleet of custom-engineered drones supporting multiple industrial applications.
- Serving Critical Industries: Solutions deployed across energy, resources, utilities and infrastructure sectors undergoing rapid digital transformation.
Key Products and Services
Virtual Plant
Virtualplant is RemSense’s flagship digital platform. It’s a high-resolution 3D asset visualisation solution that allows users to explore and interact with industrial facilities remotely, as if on site. By combining drone-based photogrammetry, terrestrial LiDAR, and 360-degree imaging, virtualplant creates immersive, detailed, interactive models of infrastructure such as gas plants, processing facilities and offshore vessels.
The platform supports a wide range of critical functions including remote inspection, maintenance planning, training, safety management, and compliance documentation. It reduces the need for site travel, improves asset visibility, and helps clients identify and address risks before they become costly failures.
Virtualplant is already deployed in high-value applications. In October 2023, Woodside Energy engaged RemSense to create a visual twin of one of its floating production storage and offloading (FPSO) vessels. In 2024, Chevron signed a series of global services agreement with RemSense to use the platform for photogrammetry scanning at gas plants in South Asia, Northwest Australia and USA, with a total contract value of more than AU$800,000. These projects reflect the platform’s global relevance and enterprise-grade capabilities.
Additional features enhance the platform’s utility:
- vTag uses AI to automatically identify and tag equipment based on nameplate data, linking it to asset registers in systems like SAP and IBM Maximo.
- vDetect automatically identifies physical defects such as corrosion, helping prioritise maintenance.
- vConnect enables real-time integration with external monitoring and data platforms, creating a unified interface for visual and operational intelligence.
These capabilities make virtualplant more than a visualisation tool, as it becomes a central intelligence layer in clients’ asset ecosystems.
RPAS (Drone) Services
RemSense has a strong legacy in drone operations, with CASA-certified pilots and a fleet of custom-engineered drones equipped with high-end imaging and sensing tools. These drone services support asset inspections, geophysical and vegetation surveys, water sampling, environmental monitoring, traffic studies, and building condition assessments.
Drone data is often the first step in creating virtualplant models. This seamless integration of field data acquisition and platform-based analysis ensures RemSense delivers a complete, end-to-end digital solution for industrial clients.
Management Team
Ross Taylor – Non-executive Chairman
Ross Taylor chartered accountant with a global finance background having worked in London, Australia, New York and Tokyo. He has held senior roles at Deutsche Bank, Bankers Trust and Barclays Capital. His experience in international capital markets brings strong governance and financial oversight to RemSense’s board.
Warren Cook – Managing Director & CEO
With over 25 years of experience in technology development and commercialisation, Warren Cook has led projects in mining, energy and environmental sectors across more than a dozen countries, including Australia, US, Brazil, Canada, France, Indonesia, South Africa and the UK. He was the CEO of acQuire Technology Solutions, delivering information management software solutions for the resources industry.
John Clegg – Non-executive Director
John Clegg has been a chartered accountant since 1965 and has supported more than 50 companies through IPOs, restructures, and strategic growth initiatives. Following his 16-year tenure at Arthur Young & Co (now Ernst & Young), he shifted focus to startup ventures, offering directorship and consulting services. As a seasoned investor, director, consultant and mentor to senior executives, Clegg has left a significant mark on numerous ventures.
BlinkLab Limited Investor Kit
- Corporate info
- Insights
- Growth strategies
- Upcoming projects